GE HealthCare Announces AI Innovation Lab Showcasing Five New Research Projects
GE HealthCare (Nasdaq: GEHC) has unveiled its new AI Innovation Lab, showcasing five early-concept AI projects aimed at revolutionizing healthcare. These innovations include:
1. Health Companion: An agentic AI project to provide multi-disciplinary medical team insights.
2. Triple negative breast cancer recurrence prediction research with Emory University.
3. Care companion initiative for enhancing maternal and infant care.
4. Multi-modal X-ray foundation model for full-body imaging analysis.
5. AI-powered mammography screening efficiency tool.
Additionally, GE HealthCare has submitted a 510(k) to the FDA for an AI-powered fetal heart rate interpretation feature. These projects are part of GE HealthCare's broader AI and digital strategy, leveraging cloud technology to drive AI development at scale.
GE HealthCare (Nasdaq: GEHC) ha presentato il suo nuovo AI Innovation Lab, mostrando cinque progetti iniziali di intelligenza artificiale destinati a rivoluzionare la sanità. Queste innovazioni comprendono:
1. Health Companion: un progetto di intelligenza artificiale agentica per fornire approfondimenti a team medici multidisciplinari.
2. Ricerca sulla previsione della recidiva del cancro al seno triplo negativo in collaborazione con l'Università di Emory.
3. Iniziativa Care Companion per migliorare la cura delle madri e dei neonati.
4. Modello fondazionale a raggi X multimodale per l'analisi delle immagini a tutto corpo.
5. Strumento per migliorare l'efficienza dello screening mammografico basato su intelligenza artificiale.
Inoltre, GE HealthCare ha presentato una domanda 510(k) alla FDA per una funzionalità di interpretazione della frequenza cardiaca fetale con intelligenza artificiale. Questi progetti fanno parte della più ampia strategia di intelligenza artificiale e digitale di GE HealthCare, che sfrutta la tecnologia cloud per promuovere lo sviluppo dell'IA su larga scala.
GE HealthCare (Nasdaq: GEHC) ha presentado su nuevo AI Innovation Lab, mostrando cinco proyectos conceptuales tempranos de inteligencia artificial destinados a revolucionar la atención médica. Estas innovaciones incluyen:
1. Health Companion: un proyecto de IA agente para proporcionar información a equipos médicos multidisciplinarios.
2. Investigación sobre la predicción de la recurrencia del cáncer de mama triple negativo con la Universidad de Emory.
3. Iniciativa Care Companion para mejorar la atención materna e infantil.
4. Modelo fundacional de rayos X multimodal para el análisis de imágenes de cuerpo completo.
5. Herramienta de eficiencia para el cribado de mamografías impulsada por IA.
Adicionalmente, GE HealthCare ha presentado un 510(k) a la FDA para una función de interpretación de la frecuencia cardíaca fetal impulsada por IA. Estos proyectos son parte de la estrategia más amplia de IA y digital de GE HealthCare, aprovechando la tecnología en la nube para impulsar el desarrollo de IA a gran escala.
GE 헬스케어 (Nasdaq: GEHC)가 의료 혁신을 혁명적으로 변화시킬 수 있는 다섯 가지 초기 개념 인공지능(AI) 프로젝트를 선보이는 새로운 AI 혁신 연구소를 공개했습니다. 이 혁신에는 다음이 포함됩니다:
1. 건강 동반자: 다양한 전문 의료 팀에 통찰력을 제공하는 능동적 AI 프로젝트.
2. 에모리 대학교와 함께 진행하는 삼중 음성 유방암 재발 예측 연구.
3. 모성 및 아기 돌봄을 향상시키기 위한 케어 동반자 이니셔티브.
4. 전신 이미지 분석을 위한 다중 모달 X-ray 기초 모델.
5. AI 기반의 유방촬영 스크리닝 효율성 도구.
추가로, GE 헬스케어는 AI 기반의 태아 심박수 해석 기능을 위해 FDA에 510(k)를 제출했습니다. 이러한 프로젝트는 GE 헬스케어의 더 넓은 AI와 디지털 전략의 일환으로, 클라우드 기술을 활용하여 대규모로 AI 개발을 촉진하고 있습니다.
GE HealthCare (Nasdaq: GEHC) a dévoilé son nouveau laboratoire d'innovation en IA, présentant cinq projets d'IA aux concepts précoces visant à révolutionner les soins de santé. Ces innovations comprennent :
1. Health Companion : un projet d'IA agentique visant à fournir des informations aux équipes médicales multidisciplinaires.
2. Recherche sur la prédiction de la récidive du cancer du sein triple négatif en collaboration avec l'Université d'Emory.
3. Initiative Care Companion pour améliorer les soins maternels et infantiles.
4. Modèle fondamental de rayons X multimodal pour l'analyse d'images corporelles complètes.
5. Outil d'efficacité pour le dépistage mammographique alimenté par l'IA.
De plus, GE HealthCare a soumis un 510(k) à la FDA pour une fonction d'interprétation de la fréquence cardiaque fœtale alimentée par l'IA. Ces projets font partie de la stratégie plus large de GE HealthCare en matière d'IA et de numérique, utilisant la technologie cloud pour favoriser le développement de l'IA à grande échelle.
GE HealthCare (Nasdaq: GEHC) hat sein neues AI Innovation Lab vorgestellt, das fünf frühe KI-Projekte präsentiert, die darauf abzielen, das Gesundheitswesen zu revolutionieren. Diese Innovationen umfassen:
1. Health Companion: Ein agentisches KI-Projekt zur Bereitstellung von Einblicken für multidisziplinäre medizinische Teams.
2. Forschung zur Vorhersage des Rückfalls bei dreifach negativem Brustkrebs in Zusammenarbeit mit der Emory University.
3. Care Companion-Initiative zur Verbesserung der Mütter- und Säuglingspflege.
4. Multimodales Röntgen-Grundmodell zur Analyse von Ganzkörperbildern.
5. KI-gestütztes Werkzeug zur Effizienzsteigerung bei der Mammographie-Screening.
Zusätzlich hat GE HealthCare beim FDA einen 510(k) für eine KI-gestützte Funktion zur Interpretation der fetalen Herzfrequenz eingereicht. Diese Projekte sind Teil der umfassenderen KI- und Digitalstrategie von GE HealthCare, die Cloud-Technologie nutzt, um die KI-Entwicklung in großem Maßstab voranzutreiben.
- GE HealthCare is investing in AI innovation to enhance healthcare outcomes and operational efficiencies
- The company is developing AI applications to improve decision-making across various disease states and care journeys
- GE HealthCare has topped the FDA list of AI-enabled device authorizations for three consecutive years with 80 authorizations
- None.
Insights
GE HealthCare's announcement of its AI Innovation Lab marks a significant step in healthcare technology advancement. The company is leveraging AI and cloud computing to address critical healthcare challenges, potentially impacting patient care and clinical workflows.
Key projects include:
- Health Companion: An agentic AI approach that could revolutionize clinical decision-making by simulating multi-disciplinary team collaboration.
- Triple negative breast cancer recurrence prediction: This could significantly improve treatment planning for an aggressive cancer type.
- Maternal and infant care solutions: Addressing preventable risks in childbirth, a pressing women's health issue.
- Multi-modal X-ray foundation model: Potentially automating medical report generation and image interpretation.
- AI-assisted mammography screening: Aiming to address radiologist shortages and improve screening efficiency.
While these projects are still in research phases, they demonstrate GE HealthCare's commitment to innovation. The company's track record of 80 FDA AI-enabled device authorizations over three years underscores its leadership in medical AI. However, the impact on GEHC's stock will depend on successful development and commercialization of these technologies.
GE HealthCare's investment in AI and cloud technology represents a strategic move to maintain its competitive edge in the medical technology sector. While the financial impact of these early-stage innovations is not immediate, they position GEHC for potential long-term growth in high-value AI-enabled medical solutions.
Key financial considerations:
- R&D Investment: Continued investment in AI research may impact short-term profitability but is important for long-term competitiveness.
- Market Opportunity: The global AI in healthcare market is projected to grow significantly, presenting substantial revenue potential.
- Regulatory Advantage: GEHC's strong track record with FDA authorizations could accelerate time-to-market for new AI products.
- Diversification: AI innovations across various medical fields (oncology, maternal health, radiology) diversify GEHC's product portfolio, potentially reducing risk.
Investors should monitor the progress of these projects through clinical validations and regulatory approvals, as successful commercialization could drive future revenue growth and market share expansion for GEHC.
- Innovations include Health Companion research project powered by agentic AI
- Additional early innovations explore pressing care needs, including identifying new ways to detect breast cancer and improving quality of care for moms and babies
"The AI Innovation Lab lifts the curtain on the work we are undertaking at the vanguard of healthcare innovation. At GE HealthCare, we're not just developing technology—we're striving to break new ground by exploring novel ways that AI could enable healthcare. For example, through projects like Health Companion, we are evaluating ways to apply agentic AI in order to bring the clinical knowledge and problem-solving insights of a multi-disciplinary medical team to clinicians’ fingertips and help them take action,” said Dr. Taha Kass-Hout, GE HealthCare's Global Chief Science and Technology Officer. “The pioneering projects we’re showcasing today are just some of the innovations we have underway, enabled by our AI and cloud computing capabilities. We will continue to gather feedback from our customers as we find ways to help them apply AI to their health data and convert information into actionable, care-enhancing strategies.”
GE HealthCare’s AI and cloud-related research and development efforts are focused on redefining the day-to-day experience of clinicians by creating new concepts to enhance the accuracy of diagnostics, reduce administrative burdens, and ensure that every patient receives the most informed, personalized care possible. Examples of these concept projects:
- Bringing the knowledge of a multi-disciplinary team to clinicians’ fingertips with agentic AI: The Health Companion project explores whether an agentic AI approach driven by multiple agents, each an expert in a particular area (i.e., genomics, radiology, pathology, etc.), could help physicians streamline their clinical decision-making and deliver more personalized care. The project’s vision is for these agents to collaborate and analyze multi-modal data in order to proactively generate treatment plan recommendations, continuously adapting based on new information. For example, GE HealthCare is exploring whether multi-agentic AI could understand the difference between an expected symptom as a function of treatment, and the same symptom as a signal of disease progression, such as cancer spread with the goal to alert the care team as appropriate with suggested next steps. Health Companion aims to provide the collaboration and discussion similar to a multi-disciplinary care team that is made up of specialized clinicians. This project is being built to incorporate safety and explainability principles.
-
Using AI to better predict triple negative breast cancer recurrence: GE HealthCare is supporting the Winship Cancer Institute of Emory University on research focused on the early prediction of triple negative breast cancer recurrence. Triple negative breast cancer is the most aggressive breast cancer subtype, however, there is a shortage of tools to predict its recurrence. Today, as many as
50% of patients diagnosed with early-stage triple negative breast cancer (stages I to III) experience recurrence.i The goal of this research is to use deep learning to evaluate multi-modal data including genomics and pathology information to investigate if AI can better predict the likelihood of recurrence, and help the care team inform a treatment plan and monitoring schedule. This research is being funded by a grant from the National Institutes of Health (NIH Grant# 1R01CA281932-01A1). Dr. Sunil Badve from Emory University is the Principal Investigator (PI), and Dr. Soumya Ghose is the Co-PI from GE HealthCare for this project.
- Innovating solutions to enhance care for moms and babies: Preventable risks associated with childbirth are one of the most pressing health issues facing women today. GE HealthCare is working directly with health systems and their care teams to develop solutions that help address this challenge. For example, GE HealthCare is working on a care companion initiative that is investigating how generative AI could minimize the effort spent searching through data and seeking best practices. Powered by a large language model, this initiative intends to further explore how to make it easy for care teams to quickly find information about standard care protocols and clinical definitions and generate patient summarizations using historical and current multi-modal data for potential use in handoffs and care transitions.
- Researching multi-modal X-ray foundation model: GE HealthCare is working on a research project to create a full-body foundation model, built on a dataset of 1.2 million anonymized PHI-free X-ray images from diverse regions across the body. This model shows great potential, and is yielding promising early internal benchmark testing on key tasks including segmentation, classification, and visual localization. The project is also experimenting with having the model automate medical report generation and interpret images into text to accelerate the workflow for radiologists, with the aim to help alleviate care teams’ administrative burdens. The goal of GE HealthCare’s research in this area is to provide practical value by reducing the cognitive burden to healthcare professionals seeking efficient and reliable tools for diagnostics. The model is being developed as a result of GE HealthCare’s strategic collaboration with Amazon Web Services.
-
Helping radiologists scale mammography screenings: Approximately
90% of screening mammograms in theU.S. are normal, yet there is no efficient way for radiologists to quickly separate the clearly normal scans from potentially suspicious ones.ii GE HealthCare is developing this cloud-based AI concept to explore how foundation models can help clinicians quickly identify normal breast screening exams, allowing radiologists to focus more of their time on suspicious cases. As countries grapple with a radiologist shortage, GE HealthCare aims to work with strategic and clinical collaborators to make advances in this space to help enhance accuracy, scale screenings, and improve access to this critical type of preventive care globally.
GE HealthCare is working on AI-enabled innovations that run the gamut in terms of maturity and market-readiness. For example, GE HealthCare has submitted a 510(k) with the
These projects showcase the groundbreaking work underway at GE HealthCare, a company that applies a 125-year legacy of innovation with the energy of a start-up as it works to help solve the healthcare industry’s most pressing challenges. GE HealthCare has been investing in AI for years and has topped an FDA list of AI-enabled device authorizations for three years in a row with 80 authorizations.iv
To learn more about these projects, visit GE HealthCare in the AI Pavilion at booth #3816 at HLTH 2024 in
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a
Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
i National Institutes of Health, “Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms,” https://reporter.nih.gov/project-details/10883284.
ii “Breast Cancer Screening (PDQ®)–Health Professional Version,” March 28, 2024, https://www.cancer.gov/types/breast/hp/breast-screening-pdq.
iii The FHR AI 510(k) has been submitted to the FDA and is not currently available for sale in
iv
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021089725/en/
GE HealthCare Media:
Sofia Mata-Leclerc
Head of Communications, Science and Technology
Sofia.Mata-Leclerc@gehealthcare.com
Source: GE HealthCare
FAQ
What is GE HealthCare's new AI Innovation Lab?
What are the five AI research projects showcased by GE HealthCare (GEHC)?
How is GE HealthCare (GEHC) addressing the challenge of triple negative breast cancer recurrence?
What is the purpose of GE HealthCare's (GEHC) multi-modal X-ray foundation model?
